TWB 103

Drug Profile

TWB 103

Latest Information Update: 11 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Transwell Biotech
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Wounds

Most Recent Events

  • 08 Nov 2016 US FDA approves IND application for TWB 103 in Wounds
  • 12 Apr 2016 Transwell Biotech plans a phase I/II trial for Wounds in USA and Taiwan (NCT02737748)
  • 01 Apr 2016 Preclinical trials in Wounds in Taiwan (Topical) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top